Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.
Publication
, Journal Article
Matthews, T; Salgo, M; Greenberg, M; Chung, J; DeMasi, R; Bolognesi, D
Published in: Nat Rev Drug Discov
March 2004
Highly active antiretroviral therapy (HAART) based on combinations of drugs that target key enzymes in the life-cycle of human immunodeficiency virus (HIV) has considerably reduced morbidity and mortality from HIV infection since its introduction in the mid-1990s. However, the growing problem of the emergence of HIV strains that are resistant not only to individual drugs, but to whole drug classes, means that agents with new mechanisms of action are needed. Here, we describe the discovery and development of enfuvirtide (Fuzeon), the first drug to inhibit the entry of HIV-1 into host cells.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Nat Rev Drug Discov
DOI
ISSN
1474-1776
Publication Date
March 2004
Volume
3
Issue
3
Start / End Page
215 / 225
Location
England
Related Subject Headings
- Quality of Life
- Pharmacology & Pharmacy
- Peptide Fragments
- Humans
- HIV-1
- HIV Fusion Inhibitors
- HIV Envelope Protein gp41
- Enfuvirtide
- Drug Resistance, Viral
- Drug Interactions
Citation
APA
Chicago
ICMJE
MLA
NLM
Matthews, T., Salgo, M., Greenberg, M., Chung, J., DeMasi, R., & Bolognesi, D. (2004). Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov, 3(3), 215–225. https://doi.org/10.1038/nrd1331
Matthews, Tom, Miklos Salgo, Michael Greenberg, Jain Chung, Ralph DeMasi, and Dani Bolognesi. “Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.” Nat Rev Drug Discov 3, no. 3 (March 2004): 215–25. https://doi.org/10.1038/nrd1331.
Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, Bolognesi D. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov. 2004 Mar;3(3):215–25.
Matthews, Tom, et al. “Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.” Nat Rev Drug Discov, vol. 3, no. 3, Mar. 2004, pp. 215–25. Pubmed, doi:10.1038/nrd1331.
Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, Bolognesi D. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov. 2004 Mar;3(3):215–225.
Published In
Nat Rev Drug Discov
DOI
ISSN
1474-1776
Publication Date
March 2004
Volume
3
Issue
3
Start / End Page
215 / 225
Location
England
Related Subject Headings
- Quality of Life
- Pharmacology & Pharmacy
- Peptide Fragments
- Humans
- HIV-1
- HIV Fusion Inhibitors
- HIV Envelope Protein gp41
- Enfuvirtide
- Drug Resistance, Viral
- Drug Interactions